Research prgress in CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2- breast cancer
10.3760/cma.j.cn121382-20200924-00112
- VernacularTitle:CDK4/6抑制剂联合内分泌治疗HR+/HER2-乳腺癌研究进展
- Author:
Weifeng SHI
- From:
International Journal of Biomedical Engineering
2021;44(1):65-70
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of advanced breast cancer is mainly palliative treatment. Endocrine therapy is the main treatment for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients without visceral crisis or life-threatening conditions. The goal of endocrine therapy is to prolong survival, improve or maintain quality of life, and delay the start of chemotherapy as much as possible. In recent years, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been approved and used clinically. CDK4/6 inhibitors are a new type of targeted therapy drugs, which are mainly used in HR+/HER2- breast cancer patients, making a breakthrough in related endocrine therapy models. Currently, the CDK4/6 inhibitors approved by the US Food and Drug Administration are Palbociclib, Ribociclib and Abemaciclib. Compared with traditional endocrine therapy alone, CDK4/6 inhibitor combined with endocrine therapy significantly prolongs the progression-free survival of breast cancer patients, and is well tolerated. In this paper, the clinical research progress in CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2- breast cancer was introduced, and the adverse reactions of three CDK4/6 inhibitors mentioned above in clinical application were analyzed.
